Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBT (2016 - 2025)

Tandem Diabetes Care's EBT history spans 13 years, with the latest figure at $4.7 million for Q4 2025.

  • For Q4 2025, EBT rose 15660.0% year-over-year to $4.7 million; the TTM value through Dec 2025 reached -$200.2 million, down 118.01%, while the annual FY2025 figure was -$200.3 million, 117.99% down from the prior year.
  • EBT reached $4.7 million in Q4 2025 per TNDM's latest filing, up from -$25.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $11.1 million in Q4 2021 to a low of -$123.6 million in Q1 2023.
  • Average EBT over 5 years is -$29.5 million, with a median of -$23.9 million recorded in 2024.
  • Peak YoY movement for EBT: plummeted 908.82% in 2022, then surged 15660.0% in 2025.
  • A 5-year view of EBT shows it stood at $11.1 million in 2021, then crashed by 245.5% to -$16.2 million in 2022, then crashed by 93.85% to -$31.3 million in 2023, then soared by 100.1% to $30000.0 in 2024, then soared by 15660.0% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's EBT are $4.7 million (Q4 2025), -$25.1 million (Q3 2025), and -$57.7 million (Q2 2025).